Levin V A, Silver P, Hannigan J, Wara W M, Gutin P H, Davis R L, Wilson C B
Department of Neurological Surgery, University of California-San Francisco Medical School 94143.
Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4. doi: 10.1016/0360-3016(90)90096-3.
Data from Northern California Oncology Group protocol 6G61, which was closed in February 1983, were reanalyzed in December 1988. The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas. PCV produced longer survival and time to tumor progression than BCNU for both histologic groups, although the difference was statistically significant only for the anaplastic gliomas. With PCV treatment, time to progression and survival doubled for anaplastic glioma patients in the 50th and 25th percentiles.
来自北加利福尼亚肿瘤学组6G61方案的数据于1983年2月结束，在1988年12月进行了重新分析。该方案要求进行一项随机试验，比较60 Gy放疗/口服羟基脲治疗联合卡莫司汀（BCNU）或丙卡巴肼、洛莫司汀（CCNU）和长春新碱（PCV）联合治疗对两种组织学分层（多形性胶质母细胞瘤和其他间变性胶质瘤）的效果。对于两个组织学组，PCV比BCNU产生了更长的生存期和肿瘤进展时间，尽管这种差异仅在间变性胶质瘤中具有统计学意义。接受PCV治疗后，第50百分位和第25百分位的间变性胶质瘤患者的进展时间和生存期增加了一倍。
